HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Checkpoint Therapeutics (NASDAQ:CKPT) and maintained a price target of $34.
August 04, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Checkpoint Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $34.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $34 indicates the firm's continued confidence in the company's potential, which could lead to increased investor interest and a potential short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100